Symbols

CBLL

CeriBell·NASDAQ

--(--)

CBLL fundamentals

CBLL Q4 2025 Earnings

CeriBell (CBLL) released its earnings on Feb 24, 2026: revenue was 24.78M (YoY +33.72%), beat estimates; EPS was -0.36 (YoY +10.00%), beat estimates.

Revenue / YoY

24.78M

+33.72%

EPS / YoY

-0.36

+10.00%

Report date

Feb 24, 2026

CBLL Earnings Call Summary for Q4,2025

Revenue Growth: Q4 2025 revenue up 34% YoY to $24.8 million, full-year up 36% to $89.1 million
New Product Launches: Neonatal/pediatric seizure detection FDA-cleared, targeting Q2 2026 launch; delirium algorithm FDA-cleared
Gross Margin Stability: Mid-80s% expected in 2026 despite tariff headwinds
2026 Guidance: $111-115 million revenue (25-29% YoY growth)
Key Risks: Ongoing patent litigation with Natus (~$10M+ annual expenses), tariff policy uncertainty
Upcoming Catalysts: Delirium pilot results (Q2 2026), LVO stroke monitoring clinical data

Earnings

EPS

Revenue

Revenue & Expenses

CBLL has released its 2025 Q4 earnings report, with revenue of 24.78M, reflecting a YoY change of 33.72%, and net profit of -13.53M, showing a YoY change of -7.56%. The Sankey diagram below clearly presents CBLL's revenue sources and cost distribution.

Key Indicators

CeriBell (CBLL) key financial stats and ratios, covering profitability, financial health, and leverage.

Income Statement

CeriBell (CBLL)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.

Trend

Breakdown

Balance Sheet

CeriBell (CBLL)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.

Trend

Breakdown

Cash Flow

CeriBell (CBLL)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.

Trend

Breakdown